Stock Events

Stock Events

PDS Biotechnology 

€0.9
0
-€0-0.22% Today

Statistics

Day High
0.9
Day Low
0.89
52W High
1.53
52W Low
0.46
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

20MayExpected
Q4 2025
Next
-0.17
-0.15
-0.13
-0.11
Expected EPS
-0.11947460000000001
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow EU6.STU. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Incyte
INCY
Mkt Cap19.36B
Incyte Corporation operates in the same biopharmaceutical space, focusing on the discovery, development, and commercialization of proprietary therapeutics, including cancer immunotherapies that compete with PDS Biotechnology's pipeline.
Merck
MRK
Mkt Cap277.02B
Merck & Co., Inc. is a global healthcare company that offers immunotherapy products, including cancer vaccines and therapies that could be seen as alternatives or competitors to PDS Biotechnology's products.
BioNTech
BNTX
Mkt Cap24.67B
BioNTech SE works on patient-specific immunotherapies for cancer and other diseases, using a wide range of therapeutic modalities that could compete with PDS Biotechnology's versatile platform.
Novavax
NVAX
Mkt Cap1.32B
Novavax, Inc. is involved in the development of vaccines for infectious diseases, which could compete with PDS Biotechnology's infectious disease vaccine candidates.
Gilead Sciences
GILD
Mkt Cap163.4B
Gilead Sciences, Inc. is a research-based biopharmaceutical company that develops and markets therapies in areas where PDS Biotechnology is also active, particularly in oncology and infectious diseases.
AMGEN
AMGN
Mkt Cap178B
Amgen Inc. is a biotechnology pioneer that develops and delivers innovative human therapeutics, including immunotherapies for cancer, which competes with PDS Biotechnology's product pipeline.
Johnson & Johnson
JNJ
Mkt Cap546.9B
Johnson & Johnson engages in the research and development, manufacture, and sale of a broad range of products in the healthcare field, including immunotherapies and vaccines that could compete with PDS Biotechnology's offerings.

About

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, focuses on developing multifunctional cancer immunotherapies. Its lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, human papillomavirus associated malignancies, and cervical cancer. The company is also developing various product candidates, which are in preclinical trials, including PDS0102 T-cell receptor gamma alternate reading frame protein (TARP) for treating prostate and breast cancers; PDS0103 (MUC-1) for ovarian, colorectal, lung, and breast cancers; and PDS0104, which include Tyrosinase-related protein 2 for the treatment of melanoma. In addition, it is developing PDS0201 for treating tuberculosis; PDS0202, an influenza vaccine candidate; and PDS0203, a vaccine for the prevention of COVID-19. The company has a license and collaboration agreements with National Institutes of Health, Merck Eprova AG, The U.S. Department of Health and Human Services, and MSD International GmbH. PDS Biotechnology Corporation was founded in 2005 and is based in Florham Park, New Jersey.
Show more...
CEO
Dr. Frank K. Bedu-Addo Ph.D.
Employees
24
Country
United States
ISIN
US70465T1079

Listings

STU
DE
EU6.STU
MU
DE
EU6.MU
BOATS
BOATS
PDSB.BOATS
XNAS
US
PDSB

0 Comments

Share your thoughts

FAQ

What is PDS Biotechnology stock price today?▼
The current price of EU6.STU is €0.9 EUR — it has decreased by -0.22% in the past 24 hours. Watch PDS Biotechnology stock price performance more closely on the chart.
What is PDS Biotechnology stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange PDS Biotechnology stocks are traded under the ticker EU6.STU.
Is PDS Biotechnology stock price growing?▼
EU6.STU stock has risen by +9.54% compared to the previous week, the month change is a +65.01% rise, over the last year PDS Biotechnology has showed a -13.51% decrease.
When is the next PDS Biotechnology earnings date?▼
PDS Biotechnology is going to release the next earnings report on May 20, 2026.
What were PDS Biotechnology earnings last quarter?▼
EU6.STU earnings for the last quarter are -0.11 EUR per share, whereas the estimation was -0.17 EUR resulting in a +35% surprise. The estimated earnings for the next quarter are N/A EUR per share.
How many employees does PDS Biotechnology have?▼
As of May 06, 2026, the company has 24 employees.
In which sector is PDS Biotechnology located?▼
PDS Biotechnology operates in the Health & Wellness sector.
When did PDS Biotechnology complete a stock split?▼
PDS Biotechnology has not had any recent stock splits.
Where is PDS Biotechnology headquartered?▼
PDS Biotechnology is headquartered in Princeton, United States.